Jones A L, Selby P
Section of Medicine, Royal Marsden Hospital, Sutton, Surrey UK.
Cancer Surv. 1989;8(4):817-36.
The anticancer effect of tumour necrosis factor (TNF) in murine tumours and in vitro has stimulated great enthusiasm for investigating its possible therapeutic role in humans. Results have now indicated that 400-800 micrograms ng/m2 of TNF may be given to patients and further dose increases are limited by hypotension and hepatic damage. At this dose, no consistent anticancer effects have yet been seen and measurement of TNF serum concentrations suggests that these effects are less than those required to induce regression of mouse tumours. TNF as a single agent is unlikely to have a major role in the treatment of cancer in humans and further studies will explore combination with other agents. During the investigation of the clinical role of TNF, observations have clarified its biological role as a mediator of inflammation and shock, cachexia and organ dysfunction.
肿瘤坏死因子（TNF）在小鼠肿瘤及体外实验中的抗癌作用激发了人们对其在人类中潜在治疗作用进行研究的极大热情。目前结果表明，可给予患者400 - 800微克/平方米的TNF，进一步增加剂量会受到低血压和肝损伤的限制。在此剂量下，尚未观察到一致的抗癌效果，TNF血清浓度测定表明这些效果低于诱导小鼠肿瘤消退所需的效果。TNF作为单一药物不太可能在人类癌症治疗中发挥主要作用，进一步的研究将探索其与其他药物联合使用的情况。在对TNF临床作用的研究过程中，观察结果阐明了其作为炎症、休克、恶病质及器官功能障碍介质的生物学作用。
